Ficolin (FCN)

Ficolins are a family of soluble pattern recognition receptors (PRRs) that play a critical role in the innate immune system by identifying and neutralizing pathogens. In humans, three distinct types exist: Ficolin-1 (M-ficolin), Ficolin-2 (L-ficolin), and Ficolin-3 (H-ficolin or Hakata antigen) [UniProt: O00602, Q15485, O75636]. These proteins are structurally characterized by a collagen-like domain and a C-terminal fibrinogen-like domain, which specifically binds to acetylated sugars such as N-acetylglucosamine (GlcNAc) on the surfaces of bacteria, fungi, and viruses [PubMed: 22444815]. Upon ligand binding, ficolins recruit Mannose-binding lectin-associated serine proteases (MASPs) to trigger the lectin pathway of the complement system, which promotes opsonization, inflammation, and direct cell lysis [PubMed: 19574571]. Beyond their protective role against infection, ficolins are heavily involved in the pathogenesis of inflammatory and autoimmune diseases. For instance, high levels of Ficolin-1 are found in the joints of patients with rheumatoid arthritis, while deficiencies in Ficolin-3 are linked to severe recurrent infections [PubMed: 28416049]. Furthermore, ficolin-mediated complement activation is a significant driver of tissue damage in ischemia-reperfusion injury and certain cardiovascular conditions [PubMed: 26366014]. While direct pharmacological inhibitors of ficolins are primarily in the experimental phase, they represent a high-value target for modulating the complement system to treat chronic inflammatory disorders and prevent excessive tissue injury during surgery or stroke [PubMed: 33177306].

Other names

Ficolin-1 (M-ficolin)Ficolin-2 (L-ficolin)Ficolin-3 (H-ficolin)Hakata antigenFCN1FCN2FCN3Collagen/fibrinogen domain-containing protein

Ficolins function by recognizing and binding to specific carbohydrate patterns or acetylated compounds on the surface of microorganisms. Once bound, they associate with Mannose-binding lectin-associated serine proteases (MASPs), which then activate the complement cascade via the lectin pathway, leading to pathogen opsonization and lysis. Therapeutic strategies involve either blocking this binding to prevent excessive complement-mediated tissue damage or using ficolin-like molecules to enhance the clearance of pathogens.